CurrentEmblemHealthPolicy AHS-T2015

Prescription Medication and Illicit Drug Testing in the Outpatient Setting - Lab Benefit Program (LBM)

Defines coverage, limitations, and reimbursement rules for presumptive and definitive outpatient drug testing (primarily urine/oral fluid) for EmblemHealth Lab Benefit Program; applies to outpatient providers submitting claims and members covered under applicable benefits.

Policy Summary

PayerEmblemHealth

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting - Lab Benefit Program (LBM)

Policy CodePolicy AHS-T2015

Change TypeNo material clinical or coverage changes

Effective DateMar 1, 2023

Next Review DateN/A

Key ActionDocument medical necessity and rationale in the medical record and obtain definitive confirmatory testing when presumptive results are positive or unexpected.

SourceLink

up to 7drug classes allowed for covered definitive testing

1-4/yrpresumptive monitoring frequency (low→high)

≤3definitive tests limit (31-90 days abstinence)

Not coveredspecimen validity testing

37.3MAmericans using illicit drugs (30 days)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Outpatient Drug Testing

Coverage criteria for outpatient drug testing — Presumptive urine/oral fluid screening

Presumptive urine/oral fluid drug screening is covered for specified clinical indications with frequency limits for monitoring.

Medical record must fully document medical necessity and rationale for testing and for any confirmatory testing.

Coverage criteria for drug testing — Workflow and interpretation

Testing workflow and interpretation expectations described in document excerpt.

Immunoassay-based presumptive urine or point-of-care testing may be used for initial screening; these assays provide rapid results but have lower sensitivity and specificity and can yield false-positives and false-negatives. Positive presumptive results should be confirmed with definitive testing as clinically indicated.

Definitive testing using chromatographic and spectroscopic methods (e.g., GC, LC, MS, MS/MS) is considered the gold standard for identifying specific drugs and metabolites and for confirmatory testing of positive presumptive results.

Providers determine the frequency and scheduling (random or scheduled) of UDT based on clinical objectives, patient risk, and documented treatment plans.

Routine immunoassays may detect drug classes but can miss synthetic or semi-synthetic opioids without specific assays; clinicians must understand assay detection capabilities, consult package inserts or laboratory personnel, and be aware of potential interpretation errors.

Detection windows vary by drug and exposure; federal/workplace cutoffs are often higher to reduce false-positives which can increase false-negatives; clinicians should be familiar with panel contents and cutoff differences when interpreting results.

UDT/DOA testing criteria and guidance

Recommendations from consensus reports and CDC regarding use and frequency of UDT for patients prescribed opioids:

Perform baseline UDT in patients prescribed opioids for chronic pain prior to initiation of therapy.

ALL of the following

At least annually for low-risk patients.
Two or more times per year for moderate-risk patients.
Three or more times per year for high-risk patients; random testing as appropriate; additional monitoring may be performed at any risk level according to clinical judgment.

Use confirmatory definitive testing (e.g., GC-MS, LC-MS/MS) when results will inform major clinical or nonclinical decisions or to clarify unexpected screening results.

Guideline-derived testing criteria

Guidance-based criteria for when and how to use toxicology testing in outpatient pain management:

Perform baseline drug testing prior to initiation of acute or chronic controlled substance therapy when clinically indicated.

Random urine drug testing is recommended for ongoing monitoring with frequency stratified by risk: low ~1-2/year; moderate ~2-4/year; high monthly or 3-4/year (guideline-dependent).

Use definitive confirmatory testing (e.g., GC/MS or LC-MS/MS) for unexpected or clinically consequential results and when precise identification of drugs is required.

Urine is the preferred and most common validated matrix; serum/plasma acceptable for anuric/dialysis patients and oral fluid acceptable for selected drugs.

Immunoassays (lab-based or POC) have specificity limitations; providers should reference package inserts or consult laboratory personnel about assay capabilities and consider definitive testing as needed.

Summarized coverage criteria and recommendations

Guidance and recommendations summarized from source organizations regarding when and how to use drug testing in clinical practice and federal programs.

ALL of the following

Recommend random UDT over scheduled UDT; frequency suggestions: low risk 1-2/year; moderate risk 3-4/year; high risk >=4/year or monthly/each visit/each refill.

SAMHSA requires testing for opioids, methadone, amphetamines, cocaine, and benzodiazepines at a minimum before admission to OTPs and recommends inclusion of benzodiazepines, barbiturates, and alcohol in panels per 2015 update; POC tests have a role but are not sufficient alone for regulatory requirements.

Federal agencies must test oral fluid specimens for marijuana and cocaine at minimum, may test for other Schedule I/II drugs and biomarkers, and may perform additional validity testing or other analyses on abnormal specimens or at MRO request; oral fluid collection allowed for pre-employment, random, reasonable suspicion, post-accident, return-to-duty, or follow-up tests.

Defines adulterated specimens and permits additional testing when abnormal characteristics or interference are identified; additional testing may be authorized case-by-case.

Regulatory and coverage guidance (informational)

Regulatory precedence and laboratory test regulation statements that inform coverage decisions and provider expectations.

When conflict exists between this Policy and applicable government policy (e.g., LCDs/NCDs or state Medicaid), the government policy will govern the coverage determination.

Laboratory-developed tests (LDTs) are regulated by CMS as high-complexity tests under CLIA '88 and are not FDA-approved; FDA clearance/approval is not required for clinical use but laboratories must validate LDTs per CMS requirements.

Coding, Assays, and Cutoffs

Non-reimbursed code classesmixedNot Covered

Any AMA definitive drug class codes

Assay typesmixed

Immunoassays (presumptive) and definitive tests (GC/MS, LC-MS/MS) for specific drugs/metabolites

Assay cutoffsmixed

DRI Cocaine Metabolite Assay cutoff 150-300 ng/mL for benzoylecgonine (urine)

Definitive testing guidancemixedCovered

Definitive testing (e.g., GC/MS or LC-MS/MS) recommended to confirm unexpected results and for specific substance identification

HHS oral fluid analytes and cut-offs (referenced screenshot)mixed

No codes listed

Procedure and Proprietary Test CodesCPT | HCPCS | mixed

80305	Drug test(s), presumptive, any number of drug classes; direct optical observation (immunoassay)
80306	Drug test(s), presumptive; instrument assisted direct optical observation (immunoassay)
80307	Drug test(s), presumptive, by instrument chemistry analyzers, chromatography, mass spectrometry
0007U	Drug test(s), presumptive, with definitive confirmation; proprietary ToxProtect (Genotox Laboratories LTD)
0011U	Prescription drug monitoring by LC-MS/MS, oral fluid; proprietary Cordant CORE™ (Cordant Health Solutions)
0051U	Prescription drug monitoring, LC-MS/MS, urine, 31 drug panel; UCompliDx (Elite Medical Laboratory Solutions, LDT)
0054U	Definitive tandem mass spectrometry, capillary blood, AssuranceRx Micro Serum (Firstox Laboratories)
0079U	Comparative DNA analysis for specimen identity verification (ToxLok™)
0082U	Drug test(s), definitive, 90+ drugs, NextGen Precision™ Testing (Precision Diagnostics)
0093U	Prescription drug monitoring, 65 common drugs by LC-MS/MS, ComplyRX (Claro Labs)

1–10 of 21

1/3

Definitive testing — drug class limit

Definitive drug classes coveredUp to seven drug classes per definitive (confirmatory) test when requested with documented rationale.

Panels larger than limitDefinitive testing for panels larger than seven drug classes is NOT covered (proprietary large-panel tests excluded).

Documentation requirementPhysician must document rationale in the medical record when ordering definitive testing.

Presumptive urine monitoring frequency by risk

Low risk monitoringPresumptive urine testing: up to once per year after initiation of chronic opioid therapy.

Provider Responsibilities, Documentation, and Billing Guidance

Note

Provider-directed testing frequency

The frequency of testing is determined by the ordering provider and may be random or scheduled based on the clinical objectives and documented risk assessment. Providers should individualize testing frequency (example guidance: baseline testing prior to initiating controlled substances; low-risk patients ~1–2 tests/year, moderate-risk ~2–4 tests/year, high-risk more frequently or at each visit as clinically indicated). Random testing is preferred over scheduled testing when feasible.

Baseline drug testing should be performed prior to initiation of acute or chronic controlled substance therapy (ASIPP and guideline-based).
Providers determine monitoring frequency and may use risk-stratified intervals (low/moderate/high) and random testing to meet monitoring objectives.

Documentation Required

Confirmatory testing requirement

Confirmatory (definitive) testing using an appropriate method (e.g., GC/MS, LC-MS/MS or other MS-based assays) is required when a presumptive point-of-care or immunoassay result is positive and the result will inform major clinical or nonclinical decisions, when results are unexpected or unexplained, or when identification of a specific drug or metabolite is necessary for patient management. Documentation in the medical record must justify the medical necessity and rationale for confirmatory testing.

Definitions and Scope

Scope / Policy description

Scope — clinical toxicologyPolicy addresses clinical toxicology in the outpatient setting; urine is the most commonly tested biological substance.

ExclusionsExcludes forensic testing and therapeutic drug monitoring (TDM).

Applicable settingApplies to outpatient providers submitting claims under the Lab Benefit Program (LBM).

Definitions list (selected abbreviations and terms)

Common abbreviations listIncludes DOA, TDM, PDMP, UDT/UDS/UDM, POC, OTP, SUD, SAMHSA, and many society acronyms used in the policy.

Term examplesExamples: 6-AM (6-acetylmorphine), EIAs (enzyme immunoassays), GC (gas chromatography), LC (liquid chromatography).

Policy Summary

PayerEmblemHealth

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting - Lab Benefit Program (LBM)

Policy CodePolicy AHS-T2015

Change TypeNo material clinical or coverage changes

Effective DateMar 1, 2023

Next Review DateN/A

Key ActionDocument medical necessity and rationale in the medical record and obtain definitive confirmatory testing when presumptive results are positive or unexpected.

SourceLink

On This Page

Toxicology testing should not be used punitively; interpret results in the context of clinical information to improve care.

Immunoassays may be sufficient for low-risk patients or when required by payers/institutions, but definitive MS-based testing is preferred for accuracy and broader detection in many chronic pain settings.

Different specimen matrices have differing detection windows and utility; clinicians should select matrices based on clinical questions and patient circumstances.

Clinicians should be familiar with panel composition, assay limitations, detection windows, and metabolism when interpreting results; inadequate knowledge can lead to interpretation errors.

Quantitative testing should not be used solely to determine adherence but may be useful for assessing variant metabolism, impurities, complex cases, or serial monitoring when indicated.

In substance use disorder treatment, frequent random testing is recommended initially (e.g., at least weekly) with reduced frequency once stability is achieved.

HHS Pain Management Task Force supports screening and monitoring in pain management and recommends payer support for compensation for screening activities and risk assessment measures.

ACOG notes routine urine drug screening is controversial; recommends validated verbal screening tools, obtaining patient consent, and use of confirmatory testing as appropriate.

Systematic reviews found variable guidance across organizations; some recommend baseline then random or periodic testing depending on the guideline and patient risk.

WHO recommends considering urine drug screening in emergency settings when intoxication, withdrawal, overdose is suspected or when the patient cannot provide accurate history.

Moderate risk monitoringPresumptive urine testing: up to two times per year after initiation of chronic opioid therapy.

High risk monitoringPresumptive urine testing: up to four times per year after initiation of chronic opioid therapy.

Example assay cutoffs and detection windows

Marijuana (THC) federal cutoffFederal workplace immunoassay cutoff referenced at 50 ng/mL (older/lower cutoffs such as 20 ng/mL discussed in detection window context).

DRI Cocaine Metabolite Assay (benzoylecgonine)Immunoassay concentration cutoff documented at 150–300 ng/mL.

Amphetamine / Methamphetamine immunoassay cutoffsExamples referenced include 500 ng/mL for amphetamine and 1,000 ng/mL for methamphetamine in some immunoassays (varies by assay).

Benzoylecgonine immunoassay cutoff range

Benzoylecgonine immunoassay cutoff range150-300 ng/mL (DRI Cocaine Metabolite Assay).

Analyte targetBenzoylecgonine is the major urinary metabolite of cocaine and the usual immunoassay target.

Detection window noteBenzoylecgonine may be detectable in urine for several days depending on exposure pattern.

Lower limit-of-detection guidance

Lower limit-of-detection useUse lower cutoff concentrations (lower limits of detection) when clinically indicated to improve detection in low-dose or intermittent users.

Clinical justificationLower cutoffs can help detect partial or low-dose use but should be applied with documented clinical rationale.

Recommendation strengthStrength of recommendation: B; Quality of evidence: II (policy notes favoring lower LOD in select circumstances).

Oral fluid testing — mandated and authorized analytes

Oral fluid mandated minimum analytesEach oral fluid specimen must be tested for marijuana and cocaine in federal HHS workplace testing requirements.

Additional testing authorizationFederal agencies may test oral fluid for other Schedule I/II drugs and perform specimen validity or biomarker testing as authorized or on MRO request.

Permitted collection circumstancesOral fluid collection is allowed for pre-employment, random, reasonable suspicion, post-accident, return-to-duty, or follow-up tests per federal guidance.

Definitive test drug-class count CPT/HCPCS thresholds

G0480 drug class thresholdG0480 — definitive drug test covering 1–7 drug classes (includes specimen validity).

G0481 drug class thresholdG0481 — definitive drug test covering 8–14 drug classes (includes specimen validity).

G0482 / G0483 thresholdsG0482 — 15–21 drug classes; G0483 — 22 or more drug classes (includes specimen validity).

Use MS-based confirmatory methods to differentiate specific opioids and metabolites or to resolve unexpected screening results.
Confirmatory testing should be supported by documentation of rationale in the patient's medical record.
Discussing unexpected screening results with patients prior to confirmatory testing can sometimes obviate the need for immediate confirmatory analysis.

Prior Authorization

Confirmatory testing and testing frequency guidance

Use confirmatory testing when results will affect major clinical or nonclinical decisions, to clarify unexpected or unexplained screening results, or when definitive identification or concentration is needed to guide management. Where confirmatory testing is indicated, follow established frequency guidance for definitive testing in substance use disorder monitoring (for example: up to weekly for 0–30 days abstinence; 1–3/month for 31–90 days; 1–3 every three months for >90 days) and limit definitive panels to seven or fewer drug classes per covered testing rules.

Restrict definitive testing panels to up to seven drug classes to meet coverage criteria; panels larger than seven drug classes are not covered.
When definitive testing is used for substance use disorder monitoring, adhere to frequency limits described in SUD monitoring guidance to avoid unnecessary or non-covered testing.

Note

ASIPP recommended UDT algorithm

Follow the ASIPP UDT algorithm: perform baseline assessment with a point-of-care (POC) immunoassay at initiation of chronic opioid therapy; if results are appropriate and explained, continue compliance monitoring with random POC immunoassay (e.g., annual or per risk level). If initial or subsequent results are inappropriate or unexplained, obtain confirmatory MS-based testing and repeat UDT within one month or at the next appointment as clinically indicated.

Baseline POC immunoassay at initiation of therapy.
Random POC immunoassay for ongoing monitoring when results are appropriate/explained (interval based on risk).
If results are inappropriate/unexplained → perform confirmatory testing and repeat UDT within ~1 month or at next visit.

Note

HHS federal oral fluid testing requirements

Federal HHS guidance for oral fluid testing requires that each oral fluid specimen be tested for at minimum marijuana and cocaine, and authorizes testing for additional Schedule I/II drugs, biomarkers, and specimen validity when requested by a Medical Review Officer or when specimen abnormalities are suspected. Federal agencies may collect oral fluid specimens for pre-employment, random, reasonable suspicion, post-accident, return-to-duty, and follow-up testing.

Oral fluid specimens must be tested for marijuana and cocaine and may be tested for other Schedule I/II drugs per the referenced panel.
Specimen validity testing and additional analyses are authorized when abnormalities or adulteration are suspected or upon MRO request.
Federal collection circumstances include applicant/pre-employment, random, reasonable suspicion/cause, post-accident, return to duty, and follow-up testing.

Documentation Required

Regulatory disclaimer / precedence

If there is a conflict between this Policy and any applicable government policy (e.g., Local Coverage Determinations, National Coverage Determinations for Medicare, or state Medicaid policies), the applicable government policy takes precedence and will be used to make coverage determinations. Providers should consult current Medicare and state Medicaid resources for up-to-date guidance.

When conflicts exist, follow the government policy (LCD/NCD or state Medicaid) over this Policy.
Medicare coverage information: https://www.cms.gov/medicare-coverage-database/search.aspx — check applicable state Medicaid sites for state-specific rules.

Reference purposeAbbreviations defined to support interpretation of testing guidance and coding sections.

Abbreviations

MSMass spectrometry (MS).

UDT / UDS / UDMUrine drug testing (UDT), urine drug screening (UDS), urine drug monitoring (UDM).

POC / SAMHSAPOC = point-of-care; SAMHSA = Substance Abuse and Mental Health Services Administration.

Test types — presumptive vs definitive

Presumptive testingInitial screening (often immunoassay) to identify presence or absence of a drug or drug class; may not distinguish structural isomers.

Definitive testingChromatography/mass spectrometry methods (e.g., GC/MS, LC-MS/MS) used to identify specific drugs/metabolites and confirm presumptive results.

POC testingPoint-of-care qualitative presumptive immunoassays performed in office/clinic with limitations; consult package insert or lab personnel for capabilities.

Benzoylecgonine (definition and relevance)

Benzoylecgonine definitionMajor urinary metabolite of cocaine; primary target of many immunoassays to detect cocaine use.

Metabolite proportionBenzoylecgonine comprises >50% of cocaine metabolites in urine; other metabolites include ecgonine methyl ester and norcocaine.

UtilityTest distinguishes cocaine use from coca leaf/tea consumption due to differing metabolites.

LC-MS/MS (definition and clinical role)

LC-MS/MS definitionLiquid chromatography-tandem mass spectrometry — a definitive testing method with higher sensitivity and broader compound detection than immunoassays.

Clinical preferenceLC-MS/MS is preferred for confirmatory testing and when precise identification is required in pain management patients.

Evidence noteStudies cited show superior sensitivity of LC-MS/MS vs immunoassays (e.g., EIA sensitivity ~78.5% in one study).

Definitive testing — definition and coverage

Definitive testing definitionQualitative or quantitative testing using chromatography and mass spectrometry (e.g., GC/MS, LC-MS) preferred over immunoassays for accurate substance identification.

When requiredUse definitive testing to confirm unexpected or clinically consequential presumptive results or when specific drug identification is needed.

Coverage noteDefinitive testing is covered (within limits) when requested with documented rationale per coverage criteria.